ERBB2 and brain neoplasm: Lapatinib does achieve higher levels in intracranial tumors of HER2+ BCBrM mouse models relative to normal brain, but the elevated levels in brain tumors are short‐lived (<12 hours), heterogenous due to differential permeability of the BTB, and below the concentrations reached in extracranial metastases.49